Figure 5From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus Plasma glucose and insulin AUC 0-4 h following glucose challenge in subjects with T2DM. Back to article page